RCAP
MBX

Resolute Capital Asset Partners’s MBX Biosciences MBX Stock Holding History

Resolute Capital Asset Partners’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-49,670
Closed -$567K – 69
2025
Q2 		$567K Buy
+49,670
New +$506K 0.3% 43

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Resolute Capital Asset Partners's MBX Position: Q3 2025 in Review

Resolute Capital Asset Partners sold out of MBX Biosciences (MBX) in Q3 2025, closing a stake of 49,670 shares — an estimated $567K sold.

Resolute Capital Asset Partners first reported a position in MBX in Q2 2025 and held it in 1 quarter. The position peaked at $567K in Q2 2025. 118 funds tracked by Wall St. Rank hold MBX as of Q3 2025.

  • Resolute Capital Asset Partners reported no remaining MBX Biosciences position as of Q3 2025 after selling out during the quarter.
  • Resolute Capital Asset Partners sold 49,670 MBX Biosciences shares in Q3 2025, an estimated $567K.
  • Resolute Capital Asset Partners first reported a position in MBX Biosciences in Q2 2025 and held it in 1 quarter.
  • Resolute Capital Asset Partners's MBX Biosciences position peaked at $567K in Q2 2025.
  • 118 funds tracked by Wall St. Rank held MBX Biosciences as of Q3 2025.

Based on Resolute Capital Asset Partners's 13F filing for Q3 2025, filed 14 Nov 2025.